Early-onset pancreatic cancer linked to advanced presentation but comparable survival

A systematic review and meta-analysis in JNCI compared clinicopathological features, treatment patterns, and survival in early-onset versus average-onset pancreatic cancer. Researchers searched five databases through January 2026 and included 48 observational studies from 15 countries using age-based definitions. Studies encompassed 1,659,432 patients, with a non-overlapping estimate of 695,936. Random-effects models pooled 39 outcomes across nine predefined domains.

Early-onset disease was associated with lower odds of diabetes (odds ratio [OR], 0.39; 95% CI, 0.21–0.72), higher odds of stage IV presentation (OR, 1.18; 95% CI, 1.02–1.36), and greater chemotherapy use (OR, 2.04; 95% CI, 1.69–2.45). Overall survival was comparable (hazard ratio, 1.03; 95% CI, 0.86–1.23), although the prediction interval was wide, at 0.50–2.12. Exploratory meta-regression suggested a nonlinear, U-shaped association between the age threshold used and survival.

These findings highlight differences in presentation and treatment without establishing a survival advantage for younger patients. GRADE certainty was very low for every outcome, and the observational evidence cannot establish treatment effects. The authors advocate equitable access to intensive multimodal therapy and germline testing before age 50, but note that stage-specific survival data are needed to confirm their observations. This update is based on the abstract; full text was unavailable.